Biohaven Ltd.
corporate_fare Company Profile
Biohaven Ltd. (NYSE:BHVN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for BHVN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for BHVN spans 8-K, 424B5, S-3ASR, 10-Q.
Recent high-impact activity:
- FDA Partial Hold on Epilepsy Drug Sends Biohaven Shares Down 14%
- FDA Pauses Enrollment in Biohaven's Epilepsy Drug Trials, Shares Drop 13%
- FDA Imposes Partial Clinical Hold on Biohaven's BHV-7000 Epilepsy Program
- Biohaven Licenses Kv7 Platform to SK Biopharmaceuticals for $400M Upfront Plus Milestones and Royalties
- Biohaven Lands $400M Upfront in Global Licensing Deal for Epilepsy Drug Opakalim
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for BHVN, detected from its recent SEC filings · based on capital-structure filings through 2026-05-04.
New ATM Offering Launched · Significant Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →